- Home
- FREY vs OBIO Comparison
FREY vs OBIO Comparison
Compare FREY & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FREY
- OBIO
- Stock Information
- Founded
- FREY 2018
- OBIO 2017
- Country
- FREY Luxembourg
- OBIO United States
- Employees
- FREY N/A
- OBIO N/A
- Industry
- FREY Industrial Machinery/Components
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- FREY Miscellaneous
- OBIO Health Care
- Exchange
- FREY Nasdaq
- OBIO Nasdaq
- Market Cap
- FREY 154.4M
- OBIO 205.0M
- IPO Year
- FREY N/A
- OBIO N/A
- Fundamental
- Price
- FREY $1.09
- OBIO $5.41
- Analyst Decision
- FREY Hold
- OBIO Strong Buy
- Analyst Count
- FREY 4
- OBIO 4
- Target Price
- FREY $1.95
- OBIO $15.75
- AVG Volume (30 Days)
- FREY 1.1M
- OBIO 45.0K
- Earning Date
- FREY 11-07-2024
- OBIO 11-11-2024
- Dividend Yield
- FREY N/A
- OBIO N/A
- EPS Growth
- FREY N/A
- OBIO N/A
- EPS
- FREY N/A
- OBIO N/A
- Revenue
- FREY N/A
- OBIO $2,079,000.00
- Revenue This Year
- FREY N/A
- OBIO $7.68
- Revenue Next Year
- FREY $414.23
- OBIO $110.40
- P/E Ratio
- FREY N/A
- OBIO N/A
- Revenue Growth
- FREY N/A
- OBIO N/A
- 52 Week Low
- FREY $0.91
- OBIO $4.22
- 52 Week High
- FREY $3.73
- OBIO $11.69
- Technical
- Relative Strength Index (RSI)
- FREY 53.92
- OBIO 52.84
- Support Level
- FREY $1.01
- OBIO $5.20
- Resistance Level
- FREY $1.04
- OBIO $5.99
- Average True Range (ATR)
- FREY 0.05
- OBIO 0.34
- MACD
- FREY 0.02
- OBIO 0.10
- Stochastic Oscillator
- FREY 100.00
- OBIO 53.60
About FREY FREYR Battery Inc.
FREYR Battery Inc is an emerging producer of clean battery solutions for the planet. It designs and manufactures high-density and cost-competitive lithium-ion batteries with a reduced carbon footprint for the markets for electric mobility, stationary energy storage, and marine and aviation applications.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.